# Autologous TAC T Cells Targeting CD19 in R/R Large B-Cell Lymphoma

> **NCT03880279** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Triumvira Immunologics, Inc.**

## Conditions studied

- Lymphoma, B-Cell

## Interventions

- **BIOLOGICAL:** TAC01-CD19

## Key facts

- **NCT ID:** NCT03880279
- **Lead sponsor:** Triumvira Immunologics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-05
- **Primary completion:** 2022-04
- **Final completion:** 2024-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Following a change in company governance, Triumvira terminated the study prior to enrolling any subjects due to a challenging competitive landscape.
- **Last updated:** 2022-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03880279

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03880279, "Autologous TAC T Cells Targeting CD19 in R/R Large B-Cell Lymphoma". Retrieved via AI Analytics 2026-09-27 from https://api.ai-analytics.org/clinical/NCT03880279. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*